2021-07-16| China

China’s Everest Medicines Partners with Tech Giant Tencent to Develop Digital Healthcare Ecosystem

by Kathy Huang
Share To

According to statistics, total digital health industry funding worldwide in 2020 reached 13.9 billion USD. The huge number is closely related to the pandemic, forcing many health providers to shift to digital solutions and kicking the industry’s digital transformation.

On July 12th, China’s Everest Medicines announced a strategic partnership with Tencent, a global technology company, to develop digital health solutions and optimize digital engagement with patients and healthcare providers in Greater China.


Using Digital Tools to Raise Disease Awareness

According to the deal, the two companies will work together to expand their own expertise in two aspects: developing disease information platforms and health management tools.

In view of the low disease awareness in China, the two companies will develop information platforms focused on diseases like cancers, kidney diseases, and severe infectious diseases to engage more patients who were out of reach in physical clinical settings. In addition, Everest Medicines will contribute its clinical developments in oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases to raise disease awareness in these fields.   


Building Accessible Health Management Ecosystem

The two companies will also build a one-stop patient management ecosystem, helping the healthcare carry out disease management ranging from diagnosis to treatment in a more information-sufficient way.

Also, they will take advantage of artificial intelligence and business intelligence tools to better identify patients’ profiles and provide guidelines for healthcares’ treatment they adopt.

“This partnership with Tencent, a global technology powerhouse, is a critical part of our overall commercial strategy,” said Kerry Blanchard, Ph.D., CEO of Everest Medicines. “It will enable us to leverage the power of digital transformation, technology, and data to strengthen our market position and ensure patients and healthcare providers in Greater China have greater access to the information and medicines they need.”

Related article: Sequanta Partners with Surging Single-Cell Genomics Startup to Serve Multi-Omics Market in China


© All rights reserved. Collaborate with us:
Related Post
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
Pioneering Partnership: Africa CDC and China CDC Elevate Public Health Initiatives
Biotheus Collaborates with BioNTech for Global Development of Cancer Therapy
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
Scroll to Top